We recommend you to use analysis of PDL BioPharma fundamentals to see if markets are today mispricing the firm. We found thirty-seven available financial ratios for PDL BioPharma which can be compared to its competitors. To make sure the equity is not overpriced, please check all PDL BioPharma fundamentals including its Price to Book, Total Debt, Number of Employees, as well as the relationship between EBITDA and Cash Flow from Operations . Please also confirm PDL BioPharma Price to Earning to check out the company can sustain itself for few more years.Use PDL BioPharma to protect against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of PDL BioPharma to be traded at $2.78 in 30 days
PDL BioPharma competes with DelMar Pharmaceuticals, Dimension Therapeutics, Denali Therapeutics, VBI Vaccines, and Vascular Biogenic. PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma operates under Biotechnology classification in USA and traded on NASDAQ. It employs 87 people.
PDL BioPharma Earnings Per Share vs Price to Earning
PDL BioPharma is considered to be number one stock in earnings per share category among related companies. It is considered to be number one stock in price to earning category among related companies reporting about 5.75 of Price to Earning per Earnings Per Share.
PDL BioPharma Systematic Risk
The output start index for this execution was fourteen with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on PDL BioPharma correlated with the market. If Beta is less then 0 PDL BioPharma generally moves in the opposite direction as compared to the market. If PDL BioPharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PDL BioPharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PDL BioPharma is generally in the same direction as the market. If Beta > 1 PDL BioPharma moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
PDL BioPharma Financial Distress Probability
Chance of Financial Distress
PDL BioPharma has less than 45 (%) percent chance of experiencing financial distress in the next 2 years of operations. More InfoPDL BioPharma is an interesting company.? They really do not make anything.? Instead, the finance patents within the pharma industry, providing financial monetization ... continue